Astellas' Phase III Front-Line AML Study Of Xospata Fails
Standard Of Care Has Shifted Since Trial's Initiation
Executive Summary
One expert said the company should focus efforts on developing the drug for maintenance treatment of AML.
You may also be interested in...
Astellas Misses Again On Xospata Label Expansion Effort
A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.
A Dramatically Changing Landscape In Acute Myeloid Leukemia
Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker